On the third day of JPM 2023, FENIX has provided coverage of presentations by other CVRM companies including Esperion, Ionis, Embecta, Amarin, and Viatris.
On the first day of JPM 2023, FENIX has provided coverage of presentations by major CVRM companies including Dexcom, Medtronic, Pfizer, Amgen, Vertex, Novartis, Cytokinetics, Teladoc, and Arrowhead. Alnylam, Gilead, J&J, Regeneron, and Amgen also presented at JPM 2023, but none had any meaningful discussion relating to their respective CVRM portfolios. Additionally, three separate CVRM-related news items have been observed: AZ announced the acquisition of CinCor Pharma (view press release), Viking completed enrollment of the Ph2b VOYAGE NASH trial (view press release), and Ionis entered into an agreement with Royalty Pharma to sell rights to Spinraza and pelacarsen (view press release).
A series of cardiometabolic-related news items have been observed: Lexicon (press release), Xeris (press release), and Ionis (press release; slides) hosted their respective Q3 ’22 earnings calls; and Esperion hosted its 2022 R&D webinar (press release; webcast) where it provided a review of the company’s pipeline, including its oral PCSK9i and ACL inhibitor programs. Below, FENIX provides highlights and insights for the respective news items.
On the final day of EASD 2022, two key news items were observed: ADA/EASD presented the updated T2DM consensus guidelines (journal publication; download slides), placing obesity management as a key consideration; and Ionis announced AstraZeneca decided not to advance their PCSK9i (ION449; AZD8233) despite achieving positive Ph2b results (press release). Below FENIX provides insights and context from the respective announcements.
Three cardiometabolic-related news items have been observed: FDA’s website has been updated noting elevated levels of NTTP have been observed in samples of sitagliptin (view here); and Senseonics (press release) and Ionis (press release; slides) hosted their respective Q2 ’22 earnings calls. Below, FENIX provides highlights and insights for the respective new items.
A series of cardiometabolic-related news items have been observed from Vertex, Medtronic, Insulet, Roche, Ionis, and state of California. Below, FENIX provides highlights and insights for the respective new items.
A series of cardiometabolic-related news items have been observed: Lilly initiated a Ph2 study evaluating LY3561774 (ANGPTL3 from Dicerna) despite the Novo Nordisk acquisition of Dicerna (view CT.gov record); and Ionis (press release; slides) and MannKind (press release) hosted their respective earnings calls. Below, FENIX provides highlights and insights for the respective new items.
Three cardiometabolic-related news items have been observed: Pfizer and Ionis announced they are discontinuing vupanorsen development for dyslipidemia following Ph2b topline results; Glooko announced it has acquired xbird; and Madrigal Pharmaceuticals announced positive topline results from its Ph3 MAESTRO-NAFLD-1 resmetirom study and hosted an associated webcast (listen to webcast here; slides). Below, FENIX provides highlights and insights for the respective new items.
On the third day of JPM 2022, FENIX has provided coverage of presentations by major CVRM companies including Akebia, Ionis, and Hikma. Additionally, a separate cardiometabolic-related news item has been observed: Oramed issued an annual message to shareholders and provided an update on the ORMD-0801 Ph3 oral insulin program for T2DM (view press release). Below, FENIX provides a topline summary of key takeaways followed by more in-depth coverage.
A series of cardiometabolic-related news items have been observed: Ionis hosted its 2022 Investor Day (view slides), and Intercept announced it has withdrawn the obeticholic acid (OCA) Marketing Authorization Application for the treatment of fibrosis due to NASH. Below, FENIX provides highlights and insights from the respective news items.